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Inflammatory Burden of Cardiac
Allograft Coronary Atherosclerotic Plaque Is
Associated With Early Recurrent Cellular Rejection
and Predicts a Higher Risk of Vasculopathy Progression
Eugenia Raichlin, MD,*† Jang-Ho Bae, MD,† Sudhir S. Kushwaha, MD,* Ryan J. Lennon, MS,‡
Abhiram Prasad, MD,* Charanjit S. Rihal, MD,* Amir Lerman, MD*†
Rochester, Minnesota
Objectives This study was designed to investigate tissue characterization of the coronary allograft atherosclerotic plaque
with virtual histology intravascular ultrasound (VH-IVUS) imaging to assess the presence and predictors of vessel
wall inflammation and its significance in cardiac allograft vasculopathy (CAV) progression.
Background A unique form of accelerated atherosclerosis, CAV remains the leading cause of late morbidity and mortality in
heart transplant patients. The pathogenesis of CAV is not fully elucidated.
Methods A total of 86 patients with coronary allograft vasculopathy underwent VH-IVUS examination of the left anterior
descending coronary artery 3.61  3.04 years following cardiac transplantation. Based on the VH-IVUS plaque
characteristics, coronary allograft plaque was divided on virtual histology intravascular ultrasound-derived “in-
flammatory” (VHD-IP) (necrotic core and dense calcium 30%) and “noninflammatory” plaque (VHD-NIP) (ne-
crotic core and dense calcium 30%). Total rejection scores were calculated based on the 2004 International
Society of Heart and Lung Transplantation rejection grading system.
Results In the whole study population, the mean percentage of fibrous, fibrofatty, dense calcified, and necrotic core
plaques in a mean length of 62.3  17.4 mm of the left anterior descending coronary artery were 50  17%,
16  11%, 15  11%, and 18  9%, respectively. Patients with a 6-month total rejection score 0.3 had signif-
icantly higher incidence of VHD-IP than those with a 6-month total rejection score 0.3 (69% vs. 33%, p 
0.011). The presence of VHD-IP at baseline was associated with a significant increase in plaque volume (2.42 
1.78 mm3/mm vs. –0.11  1.65 mm3/mm, p  0.010), plaque index (7  9% vs. 0  8%, p  0.04), and re-
modeling index (1.24  0.44 vs. 1.09  0.36, p  0.030) during 12 months of follow-up when compared with
the presence of VHD-NIP at baseline and during follow-up.
Conclusions The presence of VHD-IP as assessed by VH-IVUS is associated with early recurrent rejection and with higher sub-
sequent progression of CAV. A VH-IVUS assessment may add important information in the evaluation of trans-
plant recipients. (J Am Coll Cardiol 2009;53:1279–86) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.041i
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sardiac allograft vasculopathy (CAV) is a unique form of
ccelerated atherosclerosis and remains the leading cause of
ate morbidity and mortality in heart transplant patients
See page 1287
ccounting for 30% mortality after 5 years (1,2). Al-
hough the pathogenesis of CAV is not fully elucidated,
rom the *Division of Cardiovascular Diseases, †Center for Coronary Physiology and
maging, and ‡Division of Biostatistics, Mayo Clinic, Rochester, Minnesota.H
Manuscript received July 22, 2008; revised manuscript received December 2, 2008,
ccepted December 8, 2008.t seems to result from a complex interplay between
mmunologic and nonimmunologic factors, with conse-
uent repetitive vascular injury and a localized sustained
nflammatory response (3,4).
There is a growing body of evidence supporting the major
ontribution of inflammatory pathways to the etiology of
AV. Elevation of systemic inflammatory markers is com-
on in transplant recipients and associated with increased
isk for CAV and worse prognosis (5–8). Focal inflamma-
ion in the vessel wall (9) and the presence of vasculitis,
nvolving the entire coronary arterial system, was frequently
hown on histopathological ex vivo examinations (10).
owever, the presence and predictors of local vessel inflam-
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CAV progression has not been
established by in vivo studies.
Grayscale intravascular ultra-
sound allows rapid and accurate
measurement of plaque volume
and assessment of the progres-
sion of coronary artery disease
(11–13) but has a significant lim-
itation in the evaluation of ath-
erosclerotic plaque composition
(Fig. 1). Recent studies have
demonstrated that virtual histol-
ogy intravascular ultrasound (VH-
IVUS) offers a novel technology
to characterize the different types
of plaque morphology in vivo (e.g.,
fibrous, fibrofatty, dense calcium,
and necrotic core) (14–16). In
ative coronaries, morphological composition of atheroscle-
otic plaque was demonstrated as a useful determinant of the
laque vulnerability (17–19) and identified plaques with a
igh risk of future clinical events (20–22).
The aim of the present study was to evaluate the
ssociation between different tissue characteristics of the
oronary allograft plaque and risk factors for CAV and to
ssess its role in the progression of CAV.
ethods
rom March 2005 to November 2007, a total of 119
onsecutive cardiac transplant recipients without signs of
Abbreviations
and Acronyms
CAV  coronary allograft
vasculopathy
hsCRP  high-sensitivity
C-reactive protein
R  rejection grade
TRS  total rejection score
VHD-IP  virtual histology
intravascular ultrasound-
derived inflammatory
plaque
VHD-NIP  virtual histology
intravascular ultrasound-
derived noninflammatory
plaque
VH-IVUS  virtual histology
intravascular ultrasound
Figure 1 Grayscale IVUS Cross-Section and VH-IVUS Images
Grayscale intravascular ultrasound (IVUS) cross-section imaging (bottom) and corr
virtual histology (VH)-IVUS images (top) from patients with VH-IVUS–derived inflamnfection or acute rejection underwent VH-IVUS study
uring routine annual coronary angiography.
Of this total cohort, 72% (86 patients, 3.61  3.04 years
fter transplantation) had at least 1 site with atherosclerosis
intimal thickness 0.5 mm) and were entered into the
tudy. Of note, no significant coronary artery disease (70%
tenosis) has been demonstrated in the donor hearts at
ransplantation. However, baseline post-transplant IVUS
tudies were not routinely performed; therefore, pre-existing
ild donor disease could not be excluded.
Thirty-eight patients underwent follow-up VH-IVUS
tudy in 1 year.
Demographic and clinical patients’ data were obtained
rom the medical records. Maintenance immunosuppression
as a triple therapy regimen based on calcineurin inhibitors
r rapamycin (8,23,24) with azathioprine, or mycophenolate
ofetil and prednisone.
Routine endomyocardial biopsies were performed every
eek for 6 weeks after transplantation beginning a week
fter completing Orthoclone OKT 3 (Ortho Biotech Prod-
cts, Bridgewater, New Jersey) treatment, every 2 weeks
rom 6 weeks to 3 months, monthly from 3 to 6 months, or
n 10- to 15-day intervals following any biopsy showing an
nternational Society of Heart and Lung Transplantation
ejection grade (R) 2 based on the 2004 guidelines. A
-month total rejection score (TRS) was assigned as 0R 
, 1R  1, 2R  2, 3R  3 and normalized by dividing the
umulative scores for the total number of biopsies taken
uring the 6-month period. Because previous data (25) and
ur recent study (26) demonstrated the association of early
ecurrent rejection and subsequent development of CAV,
e chose to analyze 6-month TRS in the present study.
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April 14, 2009:1279–86 Inflammatory Burden of Heart Graft Coronary Plaqueatients were stratified into 2 groups according to cumula-
ive 6-month TRS 0.3 and 0.3 (26).
VUS examination. Intravascular ultrasound was per-
ormed after intracoronary administration of 100- to
00-g nitroglycerin. The IVUS images were recorded
rom the distal left anterior descending coronary artery to
he left main coronary artery with a commercially available
VUS console (IVUS3 system, Volcano Therapeutics,
ancho Cordova, California) and 2.9-F, 20-MHz, phased-
rray IVUS catheters (Eagle Eye Gold, Volcano Therapeu-
ics) with an automated pullback system (0.5 mm/s). The
VUS images were stored on a CD-ROM for later offline
-dimensional volumetric and VH-IVUS analysis.
H-IVUS analysis. Offline volumetric analysis of IVUS
ata was performed (Volcano Invision Gold imaging system
oftware, Volcano Corporation, Rancho Cordova, Califor-
ia) by 2 experienced operators who were unaware of clinical
ata. After automatic border detection was corrected man-
ally, morphometric parameters of the volume (cubic mil-
imeters), lumen, and plaque in the examined vessel segment
ere obtained and calculated as previously described (27).
he Simpson rule for volumetric measurement was used.
ach measured volume (vessel volume, lumen volume,
laque volume) was normalized to the examined segment
ength (cubic millimeters per millimeter) to compensate for
ifferences in examined vessel segment length. A plaque
ndex was calculated as: (plaque volume/vessel volume) 
00%. The volumetric remodeling index was calculated as:
ollow-up vessel volume/baseline vessel volume.
Each plaque segment was classified following 4 types of
haracteristics (fibrous, fibrofatty, dense calcium, and ne-
rotic core) according to the radiofrequency signal process-
ng of VH-IVUS technology (14). They were color-coded
nd displayed on the IVUS console: fibrous as green,
brofatty as light green, dense calcium as white, and
ecrotic core as red. This approach has been validated with
istological techniques (14,15,28). Because necrotic core is
haracterized histologically by a high level of lipids, necrotic
ells, remnants of lymphocytes, and microcalcification,
hich presents a by-product of dead cells, we followed the
pproach of Nair et al. (14) and combined necrotic core and
ense calcium into a single group that presumably reflects
he inflammatory burden of the cardiac allograft atheroscle-
otic plaque. Thus, based on the VH-IVUS plaque charac-
eristics, the patients were divided as those with virtual
istology intravascular ultrasound-derived “inflammatory
laque” (VHD-IP) (necrotic core and dense calcium30%)
r “noninflammatory plaque” (VHD-NIP) (necrotic core
nd dense calcium 30%). We selected this cutoff value
ased on previous pathological and in vivo VH-IVUS
ndings in a nontransplant population (16,29–31).
For the random samples of 41 patients, intraobserver
nalysis was performed at least 2 weeks apart, and interob-
erver analysis was performed by 2 experienced, independent
bservers. Intraobserver reliability of the percentage of
ecrotic core and dense calcium was 92.7%. ctatistical analysis. Data are described by mean  SD or
ounts and percentages, as appropriate. Analysis to compare
or different demographic and clinical data between the
roups was performed using the t test for continuous data
nd the chi-square test for categorical data. The Pearson
orrelation coefficient and univariate linear regression were
sed to describe associations between plaque characteristics
ssessed by VH-IVUS and risk factors for CAV. Correla-
ion coefficients of high-sensitivity C-reactive protein
hsCRP) level, for which the distribution was heavily
kewed, and 3-dimensional IVUS findings were calculated
ccording to Spearman rank correlation. Differences from
aseline to 12-month follow-up within groups were com-
ared using a paired t test. Multivariable regression was used
o assess independent predictors of plaque progression. A
alue of p  0.05 was considered to be statistically
ignificant.
esults
ur study population represents a cross section of transplant
ecipients studied at various time intervals after transplan-
ation. Eighty-six patients (mean age: 49.1  15.9 years,
ean donor age: 30.1  13.7 years) underwent the VH-
VUS study at 3.6  3.0 years after transplantation (Table 1).
H-IVUS plaque composition in heart transplant pa-
ients. In the whole study population, a mean length of
2.3  17.4 mm of the left anterior descending coronary
rtery was analyzed. The mean percentage of fibrous,
brofatty, dense calcified, and necrotic core plaques were
0  17%, 16  11%, 15  11%, and 18  9%, respectively
Table 2).
orrelation of VH-IVUS findings with 6-month TRS. Pa-
ients were stratified into 2 groups according to cumulative
-month TRS 0.3 (n  34) and TRS 0.3 (n  52).
here were no significant differences between the groups
ith regard to recipient’s sex, reason for transplantation,
old ischemic time, cytomegalovirus infection, conventional
therosclerosis risk factors, and treatment (Table 1). There
as no difference in volumetric plaque characteristics be-
ween the groups (Table 2).The percentage of necrotic core
as significantly higher in patients with 6-month TRS
0.3. There was a significantly higher incidence of
HD-IP in the group of patients with 6-month TRS0.3.
orrelation of VH-IVUS findings with other risk factors
or CAV. Time after transplantation positively correlated
ith plaque index (r  0.23, p  0.034), but there were no
ignificant correlations between the time after transplanta-
ion and plaque volume or any element of plaque
omposition.
Linear-regression analysis revealed a direct correlation
etween the donor age and the total amount (r  0.43, p 
.001) or percentage of fibrous plaque tissue (r  0.23, p 
.022).
There were no significant correlations between the plaqueomposition and lipid levels or body mass index.
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ncreased in the VHD-IP group, but the difference was not
ignificant (2.96  2.94 mg/l, n  21 vs. 1.62  1.78 mg/l,
 22; p  0.07). There was significant correlation between
sCRP level and the percentage of necrotic core (rs  0.32,
 0.03).
Patients’ Demographic, Clinical, andL bora ory Character stics Divided by TRS at 6
Table 1 Patients’ Demographic, Clinical, anLaboratory Characteristics Divided
Overall
N  86
Recipient age, yrs 49.08 15.85
Time after transplant, yrs 3.91 3.84
Recipient male sex, n (%) 55 (64%)
Reason for transplant, n (%)
Ischemic CMP 29 (31%)
Dilated CMP 27 (37%)
Other 29 (30%)
Donor age, yrs 31.10 13.69
Cold ischemic time, min 172.30 48.05
BMI at transplantation, kg/m2 26.23 5.58
Triglycerides, mg/dl 162.09 85.05
HDL cholesterol, mg/dl 58.75 19.71
LDL cholesterol, mg/dl 105.57 35.25
Hypertension, n (%) 70 (81%)
Diabetes mellitus, n (%) 17 (20%)
Cytomegalovirus viremia, n (%) 10 (12%)
ACE inhibitors, n (%) 36 (42%)
Calcium-channel blocker, n (%) 26 (30%)
Statin, n (%) 78 (91%)
CNI/sirolimus, n (%) 56 (65%)/30 (35%)
Azathioprine/MMF, n (%) 41 (48%)/45 (52%)
ACE angiotensin-converting enzyme; BMI body mass index; CMP
LDL  low-density lipoprotein; MMF  mycophenolate mofetil; TRS 
3-Dimensional and VH-IVUS Characteristics Divi
Table 2 3-Dimensional and VH-IVUS Charact
Overall
N  86
Volumetric characteristics
SL, mm 62.33 17.36
VV/SL, mm3/mm 17.53 4.62
LV/SL, mm3/mm 12.35 3.44
PV/SL, mm3/mm 5.18 2.14
Plaque index, % 29 9
Tissue type
Fibrotic, mm3/mm 0.93 1.19
Fibrofatty, mm3/mm 0.27 0.41
Dense calcium, mm3/mm 0.20 0.21
Necrotic core, mm3/mm 0.29 0.30
Fibrotic, % 50 17
Fibrofatty, % 16 11
Dense calcium, % 15 11
Necrotic core, % 18 9
VHD-IP/VHD-NIP 47 (55%)/39 (45%)
LV  lumen volume; Plaque index  percent plaque volume; PV  pl
ultrasound-derived inflammatory plaque; VHD-NIP  virtual histology intravas
histology intravascular ultrasound; VV  vessel volume; other abbreviations association between plaque morphology and CAV pro-
ression. Of the total cohort, 38 patients underwent
ollow-up VH-IVUS examinations in 12 months. Overall
ean change in plaque volume (change in plaque volume/
egment length) was 0.78  2.43 mm3/mm and mean
hange in plaque index was 4  11%. Mean remodeling
hs
S at 6 Months
TRS <0.3
n  34 (40%)
TRS >0.3
n  52 (60%) p Value
51.95 14.32 47.30 17.38 0.24
3.85 3.69 4.95 3.97 0.25
21 (63%) 34 (66%) 0.71
9 (27%) 21 (40%) 0.64
11 (32%) 16 (31%)
14 (41%) 15 (29%)
32.30 14.67 30.28 14.34 0.60
163.04 49.00 173.95 47.66 0.40
27.00 7.63 25.92 4.41 0.54
176.00 93.07 153.31 75.28 0.31
57.31 18.99 58.90 18.84 0.74
106.96 38.38 101.21 32.85 0.35
31 (91%) 39 (78%) 0.12
6 (17%) 11 (21%) 0.73
4 (12%) 6 (12%) 0.98
16 (48%) 20 (39%) 0.52
12 (35%) 14 (26%) 0.45
31 (91%) 47 (90%) 0.89
(65%)/12 (35%) 34 (66%)/18 (34%) 0.98
(52%)/16 (48%) 23 (45%)/29 (55%) 0.57
myopathy; CNI calcineurin inhibitor; HDL high-density lipoprotein;
ejection score.
y TRS at 6 Months
ics Divided by TRS at 6 Months
TRS <0.3
 34 (40%)
TRS >0.3
n  52 (60%) p Value
3.86 14.12 62.20 19.33 0.67
8.25 4.79 16.66 4.59 0.21
3.04 3.13 11.53 3.59 0.10
5.22 2.57 5.13 2.05 0.89
28 9 31 9 0.20
1.23 1.53 0.86 1.12 0.33
0.37 0.49 0.26 0.35 0.36
0.14 0.14 0.24 0.25 0.07
0.22 0.23 0.33 0.35 0.16
55 19 47 15 0.07
18 13 16 10 0.56
12 11 17 12 0.08
14 8 21 8 0.004
(33%)/23 (67%) 36 (69%)/16 (31%) 0.011
lume; SL  segment length; VHD-IP  virtual histology intravascularMont
d
by TR
22
18ded b
erist
n
6
1
1
11
aque vo
cular ultrasound-derived noninflammatory plaque; VH-IVUS  virtual
s in Table 1.
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ignificant changes in plaque composition during the 12-
onth period (Table 3).
In the patients with VHD-IP in the baseline VH-IVUS
tudy (n  20), there was significant subsequent increase in
laque volume (2.42  1.78 mm3/mm vs. –0.11  1.65
m3/mm, p  0.01) and plaque index (7  9 vs. 0  8,
 0.04) during the 1-year follow-up compared with those
ith VHD-NIP (n  18). There was significant increase in
emodeling index in the patients with VHD-IP compared
ith those with VHD-NIP (1.24  0.44 vs. 1.09  0.36, p
0.03) (Fig. 2).
Covariates that could influence plaque progression, in-
luding recipient’s sex and age at transplantation, reason for
ransplantation, cold ischemic time, body mass index, lipid
evels, 6-month TRS, and donor age, were examined, and
nly lower high-density lipoprotein cholesterol level was
ignificant when added to the model in the presence of the
laque type. When corrected for high-density lipoprotein
holesterol, the presence of the VHD-IP remained a sig-
ificant factor for changes in plaque volume and plaque
ndex.
iscussion
he current study demonstrates that the presence of inflam-
atory plaque as assessed by VH-IVUS is associated with
arly recurrent rejection and with subsequent progression of
AV. This study supports a role of interaction between the
mmune basis for onset and late inflammatory modulation
n the progression of CAV and suggests that VH-IVUS
ay be a useful tool in studying the mechanism of and for
redicting the progression of CAV.
oronary artery plaque composition assessed by VH-
VUS. Coronary artery disease of human cardiac allograft is
multifactorial phenomenon with variable morphologic
eatures. Previous histological ex vivo studies described 2
icroscopic types of coronary allograft lesions (32). One
olumetric Assessment of Vasculareo etry and Progr ssi n of Allog aftasculopathy During 12-Month Follow-Up (n  38)
Table 3
Volumetric Assessment of Vascular
Geometry and Progression of Allograft
Vasculopathy During 12-Month Follow-Up (n  38)
First 3D VH-IVUS Second 3D VH-IVUS p Value
SL, mm 54.22 18.10 58.14 15.86 0.024
VV/SL, mm3/mm 16.32 5.80 16.58 5.23 0.26
LV/SL, mm3/mm 11.58 3.99 11.06 4.39 0.08
PV/SL, mm3/mm 4.74 2.59 5.52 2.37 0.025
Plaque index, % 28 10 32 13 0.010
Fibrotic, mm3/mm 0.93 0.65 0.98 0.56 0.75
Fibrolipid, mm3/mm 0.26 0.41 0.19 0.4 0.46
Dense calcium, mm3/mm 0.20 0.21 0.17 0.28 0.48
Necrotic core, mm3/mm 0.20 0.30 0.29 0.24 0.37
Fibrotic, % 49 15 52 16 0.57
Fibrolipid, % 16 12 15 13 0.43
Dense calcium, % 15 10 14 12 0.74
Necrotic core, % 19 9 21 11 0.32tD  3-dimensional; IVUS  intravascular ultrasound; other abbreviations as in Table 2.ype of lesion is confined to the proximal region of epicardial
rteries and is indistinguishable from ordinary atherosclero-
is of native vessels. The second type is characterized by the
resence of vasculitis, involves the entire coronary arterial
ystem, and has been suggested to represent the immune-
ediated vessel injury (10). A dichotomous pattern of
oronary allograft vasculopathy was also previously sug-
ested by grayscale IVUS (33). The current study extends
hese previous observations and reports the tissue character-
zation and the heterogeneity of coronary plaque composi-
Figure 2 Progression in Plaque Volume, Plaque
Index, and Remodeling Index in IP and NIP Groups
A shows the progression in plaque volume in the inflammatory plaque (IP) and
noninflammatory plaque (NIP) groups: virtual histology intravascular ultrasound-
derived inflammatory plaque (VHD-IP) (n  21): 2.42  1.78, virtual histology intra-
vascular ultrasound-derived noninflammatory plaque (VHD-NIP) (n  17): –0.11 
1.65; p  0.01. B shows the progression in plaque index in the VHD-IP and VHD-
NIP groups: VHD-IP (n  21): 7  9, VHD-NIP (n  17): 0.1  8; p  0.04.
C shows the remodeling index in the VHD-IP and VHD-NIP groups: VHD-IP
(n  21): 1.24  0.44, VHD-NIP (n  17): 1.09  0.36; p  0.03.ion following heart transplantation assessed by VH-IVUS.
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Inflammatory Burden of Heart Graft Coronary Plaque April 14, 2009:1279–86arly rejection, systemic inflammation, and inflamma-
ory plaque burden. Cardiac allograft vasculopathy is as-
ociated with an injury of the coronary vessel endothelium
hat may be initiated by a variety of immunologic factors. It
as been demonstrated that early immunological events
urrounding engraftment lead to an inflammatory process in
he vascular endothelium (34–41). Although CAV may
evelop at any stage after transplantation, events during the
rst year, resulting most likely from initial and ongoing
mmunologically mediated injury to the vascular endothe-
ium, appear to be important in CAV pathogenesis (42).
everal clinical studies demonstrated a relationship between
mmune events and an increase in systemic inflammatory
arkers following heart transplantation (7,43). The present
tudy suggests that the association between early recurrent
ellular rejection and inflammatory burden of cardiac allo-
raft atherosclerotic plaque supports an immune basis of the
nflammatory process. In line with a study of a nontrans-
lant population that demonstrated that elevated plasma
sCRP level is associated with necrotic core volume in
atients with acute coronary syndromes (44), our study
emonstrated the association between hsCRP level and
ecrotic core of cardiac allograft coronary plaque. The
redominant VH-IVUS examination was performed late
nearly 4 years) after transplantation, indicating that sys-
emic and vascular inflammation tend to persist throughout
he course of transplantation.
nflammatory plaque and CAV progression. The evi-
ence that chronic inflammation may be a central event in
ardiac allograft vasculopathy is gaining acceptance. Several
tudies demonstrated that elevated systemic levels of the
nflammatory markers are predictive not only of car-
iac allograft vasculopathy but also of allograft failure
5–7,43,45). The present study suggested that VH-IVUS
an be used to identify patients with increased burden of
nflammatory plaque following heart transplantation and
howed that the focal inflammation as assessed by VH-
VUS is associated with subsequent progression of CAV.
In addition, the coronary arteries with VHD-IP showed
ositive remodeling in the present study. These data are
onsistent with previous findings from a nontransplant
opulation, which showed that necrotic core and inflamma-
ion are associated with expansion of the internal elastic
amina, and positive remodeling closely correlates with
laque vulnerability (46,47).
ibrotic plaque. Grayscale IVUS studies found that the
attern of atherosclerosis in many proximal segments ap-
eared similar to conventional atherosclerosis with eccentric
ocal plaques, often located near branching points and with
redominantly fibrotic morphology, and demonstrated that
he incidence of donor-derived coronary atherosclerosis is
ositively related to the donor age (33). It was shown in a
ecent VH-IVUS study (48) that fibrotic and fibrofatty
issues were predominant within 2 months following cardiac
ransplantation and associated with donor-derived coronary
rtery disease. Although there was a weak linear correlation, ihe present study demonstrated significantly increased do-
or age in recipients with predominant fibrotic plaque tissue
ven late after transplantation and suggests the association
f noninflammatory plaque with donor transmitted disease.
In the 2007 International Society of Heart and Lung
ransplantation registry, older donor age is an independent
isk factor for early CAV. Donor coronary artery disease can
erve as a starting point for CAV (2); however, the impact
f native vessel atherosclerosis on CAV progression remains
ontroversial. Several studies found no significant difference
n the rate of intimal thickening between patients with
onor hearts having pre-existing CAD and those without
49,50). Our study demonstrated relatively slow progression
f CAV in the group of patients with fibrous plaque.
tudy limitations. The predictive accuracies for VH-IVUS
emonstrated the potential of this imaging tool for analyz-
ng plaque vulnerability in a nontransplant population. This
pproach, however, has not been validated with histological
echniques in heart transplant patients. Although we spec-
lated that necrotic core and dense calcium represent the
nflammatory burden of the coronary allograft plaque, it is
ot clear if the inflammatory activity of the plaque can be
irectly visualized by VH-IVUS. Study of a large cohort of
atients is justified to evaluate the association between
laque characteristics and systemic inflammatory markers
ollowing heart transplantation. Our study, however,
howed an association between the VH-IVUS–assessed
laque characteristics, early recurrent rejection, and subse-
uent progression of CAV.
onclusions
oronary angiography has a high specificity of 97.8% but
nly moderate sensitivity of 79.3% in CAV detection (51).
he intimal changes in CAV are best detected by IVUS,
hich has become the gold standard for the early diagnosis
f CAV (12,52,53). Simultaneous assessment of virtual
istology with IVUS may add important information in the
linical evaluation of heart transplant recipients. The asso-
iation of necrotic core and spotty dense calcification as-
essed by VH-IVUS as a parameter of an inflammatory
laque with higher score for early recurrent rejection con-
rms the dual etiology for transplant coronary artery disease.
arly stratification of these high-risk lesions is desirable and
ay shed light not only on the mechanism of CAV but also
n development of a novel therapeutic approach. The
ssociation of early recurrent rejection, inflammation, and
he changes in the plaque burden suggests an interaction
etween the immune basis for onset and inflammatory
odulation for progression of CAV. Patients with an inflam-
atory plaque composition pattern that suggests possible rapid
rogression of CAV may be scheduled for more frequent
bservations and augmentation of immunosuppressive or anti-
nflammatory therapy early after transplantation.
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